Drug intelligence / Profile preview

RAU 018

Development stage: Preclinical
Modality: Small Molecules

Overview

RAU 018 is a novel aminonaphthoquinone derivative investigated for its potential as a therapeutic agent against various cancers. In preclinical studies, it has demonstrated cytotoxic, anti-angiogenic, and anti-metastatic effects on breast cancer cells (MCF-7 and MDA-MB-231), osteosarcoma cells (MG-63), and endometrial cancer cells (HEC-1A). Its efficacy is particularly noted when combined with curcumin, suggesting a synergistic effect in inhibiting cancer progression.

Beyond the preview

Go deeper on RAU 018.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RAU 018.

Explore the full profile